Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.43 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | TEK | Q02763 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14476560 | 0.89 | AGTR1 (0.42) | PLA2G7AGTR1CCR9TP53TEK | |
| SCHEMBL14476627 | 0.83 | PLA2G7 (0.48) | PLA2G7AGTR1CHKA | |
| SCHEMBL14476842 | 0.80 | CCR9 (0.42) | AGTR1CCR9TP53TEKKDR | |
| SCHEMBL14476246 | 0.79 | FNTA (0.48) | HRH3TEKCHKAEPHB4 | |
| SCHEMBL14476863 | 0.79 | KDM4E (0.52) | PLA2G7AGTR1CCR9TP53HRH3 | |
| SCHEMBL14476620 | 0.76 | POLB (0.48) | AGTR1TP53CHKA | |
| SCHEMBL14476621 | 0.74 | CCR9 (0.42) | AGTR1CCR9TP53TEKKDR | |
| SCHEMBL15653992 | 0.74 | CCR9 (0.56) | AGTR1CCR9TP53 | |
| SCHEMBL14476245 | 0.74 | MAPT (0.47) | CCR9 | |
| SCHEMBL14476267 | 0.72 | PPARG (0.41) | AGTR1CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2014-06-19 | — | — | US | disclosed |
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2014-06-19 | — | — | US | disclosed |
| EP-2725024-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013000267-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | 中国科学院上海药物研究所 (CN) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013000108-A1 | AZOLE HETEROCYLIC COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 中国科学院上海药物研究所 (CN) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | PLA2G5, LTA4H, PLA2G4A | PLA2G7 10/4885AGTR1 950/4885CCR9 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.